Πλοήγηση ανά Συγγραφέα "Goulis, J."
-
Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis
Zachou, K.; Gampeta, S.; Gatselis, N. K.; Oikonomou, K.; Goulis, J.; Manoussakis, M. N.; Renaudineau, Y.; Bogdanos, D. P.; Dalekos, G. N. (2015)Background & AimsAntibodies (Abs) to soluble liver antigen/liver pancreas (anti-SLA/LP) are considered markers of worse prognosis and outcome in patients with autoimmune hepatitis (AIH) although this assumption has recently ... -
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Buti, M.; Goulis, J.; Arends, P.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L. A.; Lampertico, P. (2015)Background & Aims: The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We evaluated the incidence and predictors of ...